Bictegravir is an integrase inhibitor used as part of a complete single-tablet HIV regimen. It belongs to the same class as dolutegravir and works in a similar way. This guide explains what bictegravir is, how it is used, what to expect in terms of side effects, and the safety points a treating doctor keeps under review.
Bictegravir is often abbreviated to BIC and is supplied together with two NRTIs in one tablet rather than as a standalone medicine.
| Important note This article is general information about medicines used in HIV care. It does not include dosing instructions and is not a substitute for medical advice. All HIV medicines are prescription-only and are selected, started, and changed by a qualified doctor. |
Quick Summary / Key Takeaways
|
Bictegravir is an integrase inhibitor used as part of a complete single-tablet HIV regimen. It belongs to the same class as dolutegravir and works in a similar way. This guide explains what bictegravir is, how it is used, what to expect in terms of side effects, and the safety points a treating doctor keeps under review.
Bictegravir is often abbreviated to BIC and is supplied together with two NRTIs in one tablet rather than as a standalone medicine.
Bictegravir is an antiretroviral medicine in the integrase inhibitor class, described in the guide to integrase inhibitors. It is not taken on its own. It comes combined with two NRTIs in a single tablet, forming a complete regimen in one daily dose.
Like other medicines in its class, bictegravir blocks the integrase enzyme. HIV depends on this enzyme to insert its genetic material into the DNA of human immune cells. Once that step is blocked, the virus cannot establish itself in the cell or produce new copies, and the amount of virus in the body falls.
| Feature | Bictegravir | Dolutegravir |
|---|---|---|
| Class | Integrase inhibitor | Integrase inhibitor |
| How supplied | Within a complete single-tablet regimen | Alone or within combinations such as TLD |
| Availability in India | More limited | Widely available |
| Barrier to resistance | High | High |
| Place in guidance | An option where suitable | Preferred anchor in current guidance |
Both medicines are effective members of the same class. Current World Health Organization guidance names dolutegravir-based regimens as the preferred option, and dolutegravir is more widely available in India, as covered in the guide to dolutegravir and bictegravir.
Bictegravir is generally well tolerated. Where effects occur, they tend to be mild and appear early, often settling as the body adjusts. Reported effects include:
| Myth | Fact |
|---|---|
| Bictegravir is taken as a single medicine. | It is supplied combined with two NRTIs in one tablet. |
| Newer means less reliable. | It is a well studied member of an established class. |
| It works differently from dolutegravir. | Both block the same integrase enzyme in the same broad way. |
| A single tablet means weaker treatment. | One tablet can contain a complete, fully effective regimen. |
| Monitoring is unnecessary once treatment is stable. | Routine follow-up continues to confirm treatment is working well. |
| When to Consult a Doctor Medical advice is appropriate before starting or changing bictegravir, where side effects appear or persist, and where other medicines or supplements are being taken. A consultation can be arranged through an HIV doctor consultation. |
Bictegravir blocks the integrase enzyme that HIV needs to insert itself into human cells, and is supplied as part of a complete single-tablet regimen. It sits alongside dolutegravir in the same effective class, with dolutegravir remaining the preferred and more widely available option in India. Suitability in any individual case is decided by a treating doctor.
For expert guidance on HIV treatment options, TAAL+ Healthcare offers HIV treatment & ART care and a confidential HIV doctor consultation.
Bictegravir is an antiretroviral medicine in the integrase inhibitor class. It blocks the enzyme HIV needs to insert its genetic material into human immune cells, and is supplied combined with two NRTIs in a single tablet.
It is used as part of a complete single-tablet regimen for HIV treatment, either for people starting therapy where the doctor considers it suitable, or as an option when a regimen is being changed.
Both belong to the integrase inhibitor class and work in the same broad way, with a high barrier to resistance. Dolutegravir is more widely available in India and is named the preferred anchor in current guidance.
It is generally well tolerated. Where effects occur they are usually mild and early, including headache, nausea, changes in sleep, or tiredness, and these often settle as the body adjusts.
No. Bictegravir comes combined with two NRTIs in one tablet, forming a complete regimen in a single daily dose rather than being taken as a standalone medicine.
Certain medicines, supplements, and mineral-containing products can affect how it is absorbed. A treating doctor reviews everything being taken, including over-the-counter items, before and during treatment.
Routine follow-up includes checks on treatment response through viral load testing, along with review of kidney and liver function and any changes in body weight associated with the class.
Yes. A single tablet can contain a complete regimen with the same active ingredients that would otherwise be taken separately, and is designed to make daily treatment simpler.
+91 98925 15959
Before You Go
The HIV Test Kit Is Still FREE
A private HIV self-test, delivered in plain packaging. Result in 20 minutes, at home. No cost, no clinic visit, and a TAAL+ doctor on call whichever way it goes.
Offer valid only in India till 30 September 2026. T&Cs apply.
